T1期结直肠癌原发内镜切除与手术的长期结局:系统综述与Meta分析
该系统综述与Meta分析纳入17项研究共19979例患者,比较内镜切除与手术治疗T1期结直肠癌的长期结局。原发内镜切除与原发手术在总生存、无复发生存和疾病特异性生存方面无显著差异,且内镜切除的手术相关不良事件比例显著更低。作者认为内镜切除应被视为可内镜切除T1期结直肠癌的一线治疗。
要点
- 原发内镜切除与原发手术的总生存、无复发生存和疾病特异性生存均无显著差异。
- 原发内镜切除的手术相关不良事件比例为2.3%,显著低于原发手术的10.9%(P < .001)。
- 非治愈性切除后追加手术与初次手术的无复发生存无显著差异。
核心结论
- 作者认为内镜切除应被视为可内镜切除T1期结直肠癌的一线治疗。
- 非治愈性切除时,追加手术的结局与初次手术相当。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Cochrane数据库截至2019年10月。
- 纳入17项已发表研究,共19979例患者。
- 研究间中位随访时间为36个月。
- 基于事件发生时间计算风险比(HR)。
主要发现
- 原发内镜切除与原发手术的总生存为79.6% vs 82.1%(HR 1.10;95%CI 0.84-1.45),无显著差异。
- 原发内镜切除与原发手术的无复发生存为96.0% vs 96.7%(HR 1.28;95%CI 0.87-1.88),无显著差异。
- 原发内镜切除与原发手术的疾病特异性生存为94.8% vs 96.5%(HR 1.09;95%CI 0.67-1.78),无显著差异。
- 追加手术与初次手术的无复发生存无显著差异(HR 1.27;95%CI 0.85-1.89)。
- 原发内镜切除的手术相关不良事件比例为2.3%,低于原发手术的10.9%(P < .001),差异显著。
临床怎么用
- 作者认为内镜切除应被视为可内镜切除T1期结直肠癌的一线治疗。
- 非治愈性切除时,追加手术的结局与初次手术相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: There is controversy over the best therapeutic approach for T1 colorectal cancer. We performed a systematic review and meta-analysis of long-term outcomes of endoscopic resection (ER) vs those of primary or additional surgery. METHODS: We performed a systematic review of the PubMed, Embase, and Cochrane databases through October 2019 for studies that reported outcomes (overall survival, disease-specific survival, recurrence-free survival at 5 years, recurrence, and metastasis) of ER vs surgery in patients with colorectal neoplasms. Hazard ratios (HR) were calculated based on time to events. RESULTS: In total, 17 published studies with 19,979 patients were included. The median follow-up time among the studies was 36 months. The meta-analysis found no significant differences between primary ER and primary surgery in overall survival (79.6% vs 82.1%, HR, 1.10; 95% CI, 0.84-1.45), recurrence-free survival (96.0% vs 96.7%, HR, 1.28; 95% CI, 0.87-1.88), or disease-specific survival (94.8% vs 96.5%; HR, 1.09; 95% CI, 0.67-1.78). Additional surgery and primary surgery did not produce significant differences in recurrence-free survival (HR, 1.27; 95% CI, 0.85-1.89). A significantly lower proportion of patients who underwent primary ER had procedure-related adverse events (2.3%) than patients who underwent primary surgery (10.9%) (P < .001). Lymphovascular invasion and rectal cancer, but not depth of submucosal invasion, were independently associated with recurrence for all T1 colorectal cancers. CONCLUSIONS: In a systematic review and meta-analysis, we found that ER should be considered as the first-line treatment for endoscopically resectable T1 colorectal cancers. In cases of noncurative resection, additional surgery can have comparable outcomes to primary surgery.
引用
- Yeh JH, Tseng CH, Huang RY, et al. Long-term Outcomes of Primary Endoscopic Resection vs Surgery for T1 Colorectal Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32526343. doi:10.1016/j.cgh.2020.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。